Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a prominent global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction, joins forces with the Israel Institute for Biological Research (IIBR) to propel the fight against emerging diseases and potential bio-threats. In a concerted effort, Dyadic and IIBR, along with its commercial arm Life Science Research Israel (LSRI), are poised to revolutionize the landscape of disease treatment and prevention.

This collaboration harnesses Dyadic's unparalleled expertise in microbial platforms for flexible-scale protein bioproduction, synergizing with IIBR's pioneering capabilities in antibodies and antigens discovery. The objective is clear: to develop and manufacture innovative solutions to combat global health challenges, including emerging diseases and bio-threats. Through a shared vision of advancing patient care, both entities strive to bring forth effective treatments and vaccines, with a focus on future commercialization through collaborative out-licensing initiatives (subject to the negotiation and execution of a binding agreement).

Mark Emalfarb, CEO of Dyadic, expressed enthusiasm for the partnership's progression, citing the IIBR's pivotal role in enhancing Dyadic's C1 cell lines using proprietary gene sequences. This enhancement aims to bolster biomanufacturing capabilities for recombinant vaccines and neutralizing agents, including targeted antigens and monoclonal antibodies. Emalfarb highlighted the significance of this joint endeavor in addressing emerging diseases, underscoring the commitment to global accessibility and affordability of vaccines and antibodies.

Baruch Shahar, LSRI's general manager, underscored the longstanding collaborative history with Dyadic, tracing back to January 2018 and extending through the pandemic. Shahar emphasized the satisfaction derived from ongoing collaborations utilizing Dyadic's C1 technology to co-develop vaccines and treatments targeting biological outbreaks. The collaboration's primary goal is to expedite the development of safe, protective, and efficacious vaccines and treatments against various biothreat agents, spanning toxins, viruses, and bacteria. Leveraging Dyadic's C1 protein expression platform, these products can be manufactured swiftly, at scale, and cost-effectively, promising a transformative impact on global healthcare.

Dyadic and IIBR remain steadfast in their commitment to driving innovation, with the shared objective of safeguarding public health and mitigating the impact of emerging diseases and bio-threats worldwide